First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers,
Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.
New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove
Harbour BioMed (HKEX: 02142, the “Company”), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and
Climate change and conflict are fuelling a resurgence of cholera in Africa, with progress toward elimination undermined by chronic underfunding, according to new analysis.
The FDA on Friday approved Mirum Pharmaceuticals’ Ctexli to treat adults with cerebrotendinous xanthomatosis (CTX), a rare, progressive and genetic disease. The approval is based
Celia Witten, deputy director of the FDA’s Center for Biologics Evaluation and Research, has left the FDA, adding to a wave of departures at the
Teva and its partner Alvotech on Friday followed Amgen in launching a biosimilar to Johnson & Johnson’s blockbuster immunosuppressive biologic Stelara, offering a steep discount
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Plus, news about MeiraGTx, Hookipa and Poolbeg Pharma: A pair of $500M share buybacks: Exelixis and Sign up to read this article for free. Get